bioAffinity Technologies, Inc. (BIAFW) cash flow statement

BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value

$0.24+0.00 (0.00%)

Close on Oct 30, 2026Market cap $23.58MP/E –Yield –

bioAffinity Technologies, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation & Amortization	0.50	0.61	0.25	0.01	0.00
Stock-Based Compensation	0.67	0.99	0.75	0.25	0.04
Change in Accounts Receivable	0.60	-0.33	0.31	-0.01	–
Change in Inventory	-0.03	-0.01	-0.01	-0.01	–
Change in Accounts Payable	-0.23	0.38	-0.01	0.11	0.04
Change in Unearned Revenue	0.02	-0.01	0.03	–	–
Operating Cash Flow	-9.33	-7.26	-6.04	-4.07	-2.05
Capital Expenditures	-0.06	-0.08	-0.02	-0.22	–
Acquisitions	–	–	-2.19	–	–
Investing Cash Flow	-0.06	-0.08	-2.21	-0.22	–
Short-Term Debt Issued (Repaid), Net	-0.05	0.19	-0.25	0.56	–
Financing Cash Flow	15	5.63	-0.34	14	3.33
Net Change in Cash	5.34	-1.72	-8.59	10	1.28
Free Cash Flow	-9.39	-7.34	-6.06	-4.29	–
Income Taxes Paid	0.02	0.02	0.02	0.03	0.00
Interest Paid	0.04	0.01	0.04	0.00	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -209.8%
Net margin: -257.3%
Return on equity, FY2025: -301.8%

Financial strength

Current ratio: 1.44
Debt to equity: 0.01
Debt to assets: 0.5%
Cash to current liabilities: 90.6%

Valuation

P/E ratio: –
Price to sales: 4.00
Price to book: 6.26
Dividend yield: –